4-dehydrowithaferin A manufacturers
|
| | 4-dehydrowithaferin A Basic information |
| Product Name: | 4-dehydrowithaferin A | | Synonyms: | 4-dehydrowithaferin A;4-oxo Withaferin A;Ergosta-2,24-dien-26-oic acid, 5,6-epoxy-22,27-dihydroxy-1,4-dioxo-, δ-lactone, (5β,6β,22R)- | | CAS: | 6850-30-2 | | MF: | C28H36O6 | | MW: | 468.58 | | EINECS: | | | Product Categories: | | | Mol File: | 6850-30-2.mol |  |
| | 4-dehydrowithaferin A Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMF: 5mg/mL; DMSO: 5mg/mL; DMSO:PBS (pH 7.2) (1:1): 0.5mg/mL | | form | A crystalline solid |
| | 4-dehydrowithaferin A Usage And Synthesis |
| Description | 4-oxo Withaferin A is a derivative of the steroidal lactone withaferin A that has anticancer activity.1 It is cytotoxic to A2780 ovarian cancer cells and carboplatin-resistant A2780 (A2780/CP70) cells (IC50s = 7.3 and <1 μM, respectively) and is 4.4-fold selective for A2780 cells over non-cancerous ARPE19 cells. | | Uses | 4-Dehydrowithaferin A is the analogue of withaferin A. Withaferin A is a withanolide isolated from Withania somnifera. 4-Dehydrowithaferin A has the potential for the research of multiple myeloma[1]. | | References | 1. Perestelo, N.R., Llanos, G.G., Reyes, C.P., et al. Expanding the chemical space of withaferin A by incorporating silicon to improve its clinical potential on human ovarian carcinoma cells J. Med. Chem. 62(9),4571-4585(2019). |
| | 4-dehydrowithaferin A Preparation Products And Raw materials |
|